Other than ibrutinib, individuals with M-CLL, devoid of TP53 aberrations and suit ample to tolerate FCR therapy, should still be very good candidates for that latter, Together with the benefit becoming that this remedy could be completed in 6 months although ibrutinib needs to be taken indefinitely.